Officially recognised as effective against SARS-CoV-2 (COVID-19) under EU Standards EN14476: 2013 + A2:2019. Read More

Viridis

Anti-bacterial Disinfectant and Hand Sanitiser

Contact Us

The importance of residual efficacy 

Residual efficacy is the residual microbiocidal or antimicrobial effectiveness of the disinfectant when it is applied on surfaces. It measures the ability of the disinfectant to inactivate microbes. Viridis has undergone extensive testing to measure its effectiveness in not only destroying microbes but also in inhibiting the growth of microbes long after it has dried.

Clinically proven through independent testing  

Viridis has been rigorously tested against testing protocols including: EN1276, EN13697, EN1650, EN 14476, residual efficacy, residue tests, taint tests, biofilm removal and halal-certification. Viridis complies with EN14476:2013 + A2:2019 and meets the minimum requirements set by EU standards to allow a claim to be effective against COVID-19. This covers all enveloped viruses including the coronavirus.

Besides our in-house laboratories, clinical testing on our products have also been done at independent laboratories in the UK and Germany. These include the Campden BRI Laboratory (UK), the Blutest Laboratory (UK), the Dr Brill and Dr Steinmann Laboratory (Germany), and the Center of Virus and Vaccine Research, Sunway University (Malaysia).

Meeting stringent international and local requirements   

Viridis has met the stringent requirements set by the European EN Standards, which evaluate the efficacy of disinfectants against microbes. Viridis has also been tested in childcare and dental settings as well as on micro-organisms isolated from hospitals; such as  methicilin resistant Staphalococcus Aureas (MRSA), E Coli and Pseudomonas Aeruginosa , in Malaysia, under local conditions. Through independent testing, Viridis has been proven to have high antimicrobial efficacy, long residual efficacy and is capable of inactivating a broad spectrum of harmful microorganisms. Here are the results of the EN tests:

Effective log reduction against a broad spectrum of microbes

Log reduction is the extent to which the disinfectant is capable of reducing the number of microbes on a surface. A 4-log and 5-log reduction means a disinfectant is able to reduce the number of microbes by 10,000-fold and 100,000-fold respectively after it has been applied to a surface. In other words, it is able to kill 99.99% (4-log reduction) and 99.999% (5-log reduction) of microbes.

Viridis has been tested to be effective to perform at log 4-5 reductions in killing pathogens, over a 24-hour period, with 8 wear cycles, on surfaces. This means that after applying on surfaces with Viridis, it is able to kill up to 99.999% of microbes on the surfaces and continues to prevent pathogens from proliferating or re-contaminating for up to 24 hours, up to 8 wear cycles.

Our products have been tested independently and are able to protect against a broad spectrum of microbes, including:

  • • Staphylococcus aureus
  • • Escherichia coli
  • • Enterococcus hirae
  • • Pseudomonas aeruginosa
  • • Listeria monocytogenes
  • • Candida albicans
  • • Murine norovirus
  • • HFMD
  • • Mycobacterium terrae
  • • EV-A71
  • • DENV
  • • Vaccinia virus

Field testing by established research institutions

SurfaceTech has also engaged, on a consulting basis, established research laboratories including the Center of Virus and Vaccine Research of Sunway University (Malaysia), and the University of South Africa to validate our test results and verify the efficacy of our products in live settings with our local and international clients.

In Malaysia, we have an ongoing consulting agreement with the Center of Virus and Vaccine Research of Sunway University to independently verify our testing claims and to conduct ongoing testing procedures for existing and prospective clients in various industries and sectors. Viridis products have been successfully tested in childcare and dental settings on a whole hosts of pathogens, including micro-organisms (commonly associated with HAIS) isolated from hospitals - such as Methicilin Resistant Stapholococcus (MRSA), E Coli and Pseudomaonas Aeruginosa - under local conditions.